Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening

Journal of Medicinal Chemistry

Volumn 54, Issue 18, 2011, Pages 6197-6205

  Axerio Cilies, Peter ^a   Lack, Nathan A ^a   Nayana, M Ravi Shashi ^a   Chan, Ka Hong ^a   Yeung, Anthony ^a   Leblanc, Eric ^a   Guns, Emma S Tomlinson ^a   Rennie, Paul S ^a   Cherkasov, Artem ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; LIGAND;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PROCESS OPTIMIZATION; PROSTATE CANCER; PROTEIN INTERACTION; SCREENING; TRANSCRIPTION INITIATION;

ANDROGEN ANTAGONISTS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 80052819425     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200532b     Document Type: Article

References (30)

1. Damber, J. E.; Aus, G. Prostate cancer Lancet 2008, 371, 1710-1721 (Pubitemid 351671887)
2. Taplin, M. E.; Rajeshkumar, B.; Halabi, S.; Werner, C. P.; Woda, B. A.; Picus, J.; Stadler, W.; Hayes, D. F.; Kantoff, P. W.; Vogelzang, N. J.; Small, E. J. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663 J. Clin. Oncol. 2003, 21, 2673-2678 (Pubitemid 46606310)
3. Tilley, W. D.; Limtio, S. S.; Horsfall, D. J.; Aspinall, J. O.; Marshall, V. R.; Skinner, J. M. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis Cancer Res. 1994, 54, 4096-4102 (Pubitemid 24258115)
4. Gao, W. Q.; Bohl, C. E.; Dalton, J. T. Chemistry and structural biology of androgen receptor Chem. Rev. 2005, 105, 3352-3370 (Pubitemid 41430813)
5. Zhou, X. E.; Suino-Powell, K. M.; Li, J.; He, Y. Z.; MacKeigan, J. P.; Melcher, K.; Yong, E. L.; Xu, H. E. Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor J. Biol. Chem. 2010, 285, 9161-9171
6. Georget, V.; Terouanne, B.; Nicolas, J. C.; Sultan, C. Mechanism of antiandrogen action: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor Biochemistry 2002, 41, 11824-11831
7. Fang, Y. F.; Fliss, A. E.; Robins, D. M.; Caplan, A. J. Hsp90 regulates androgen receptor hormone binding affinity in vivo J. Biol. Chem. 1996, 271, 28697-28702 (Pubitemid 26374699)
8. 2-terminal and steroid-binding domains J. Biol. Chem. 1993, 268, 19004-19012 (Pubitemid 23273853)
9. Tran, C.; Ouk, S; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009, 324, 787-790
10. Attar, R. M.; Jure-Kunkel, M.; Balog, A.; Cvijic, M. E.; Dell-John, J.; Rizzo, C. A.; Schweizer, L.; Spires, T. E.; Platero, J. S.; Obermeier, M.; Shan, W.; Salvati, M. E.; Foster, W. R.; Dinchuk, J.; Chen., S. J.; Vite, G.; Kramer, R.; Gottardis, M. M. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer Cancer Res. 2009, 69, 6522-6530
11. Foster, W. R.; Car, B. D.; Shi, H.; Levesque, P. C.; Obermeier, M. T.; Gan, J.; Arezzo, J. C; Powlin, S. S.; Dinchuk, J. E.; Balog, A.; Salvati, M. E.; Attar, R. M.; Gottardis, M. M. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists Prostate 2011, 71, 480-488
12. Chen, Y.; Clegg, N. J.; Scher, H. I. Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target Lancet Oncol. 2009, 10, 981-991
13. Chen, Y.; Sawyers, C. L.; Scher, H. I. Targeting the androgen receptor pathway in prostate cancer Curr. Opin. Pharm. 2008, 8, 440-448
14. Gunther, J. R.; Parent, A. A.; Katzenellenbogen, J. A. Alternative inhibition of androgen receptor signaling: Peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors ACS Chem. Biol. 2009, 4, 435-440
15. Joseph, J. D.; Wittmann, B. M.; Dwyer, M. A.; Cui, H. X.; Dye, D. A.; McDonnell, D. P.; Norris, J. D. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 12178-12183
16. Estebanez-Perpina, E.; Arnold, A. A.; Nguyen, P.; Rodrigues, E. D.; Mar, E.; Bateman, R.; Pallai, P.; Shokat, K. M.; Baxter, J. D.; Guy, R. K.; Webb, P.; Fletterick, R. J. A surface on the androgen receptor that allosterically regulates coactivator binding Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 18874-18874
17. Irwin, J.; Shoichet, B. The ZINC database as a new research tool for ligand discovery Abstr. Pap.-Am. Chem. Soc. 2005, 230 U1009
18. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749 (Pubitemid 38380917)
19. Zsoldos, Z.; Reid, D.; Simon, A.; Sadjad, S. B.; Johnson, A. P. eHiTS: A new fast, exhaustive flexible ligand docking system J. Mol. Graphics Modell. 2007, 26, 198-212 (Pubitemid 46977244)
20. Chemical Computing Group, Inc. (CCG). Molecular Operating Environment (MOE); CCG: Montreal, Quebec, Canada, 2008; www.chemcomp.com.
21. Schrödinger. Maestro; Schrödinger: New York, 2008; www.schrodinger.com.
22. Culig, Z.; Hoffmann, J.; Erdel, M.; Eder, I. E.; Hobisch, A.; Hittmair, A.; Bartsch, G.; Utermann, G.; Schneider, M. R.; Parczyk, K.; Klocker, H. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system Br. J. Cancer 1999, 81, 242-251 (Pubitemid 29423702)
23. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-317 (Pubitemid 38499758)
24. Tavassoli, P.; Snoek, R.; Ray, M.; Rao, L. G.; Rennie, P. S. Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells Prostate 2007, 67, 416-426 (Pubitemid 46341083)
25. Tirat, A.; Freuler, F.; Stettler, T.; Mayr, L. M.; Leder, L. Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins Int. J. Biol. Macromol. 2006, 39, 66-76 (Pubitemid 44066539)
26. Kenakin, T. P. Pharmacologic Analysis of Drug-Receptor Interaction; Lippincott Williams & Wilkins (LWW): Philadelphia, PA, 1997.
27. www.invitrogen.com.
28. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 (Pubitemid 47080256)
29. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 (Pubitemid 27235885)
30. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501